Klaus Pantel

Dissecting the metastatic cascade.

Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives.

Influence of immunomagnetic enrichment on gene expression of tumor cells.

Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity.

Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells.

Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.

Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells.

High incidence of EMMPRIN expression in human tumors.

Lymphatic spread and microinvolvement in adenocarcinoma of the esophago-gastric junction.

Recent translational research: circulating tumor cells in breast cancer patients.

Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia.

Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer.

Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system.

Central mesenteric lymph node BER-Ep4+ cells in colorectal cancer: challenge to sentinel node concept?

Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters.

Short tandem repeat polymorphism in exon 4 of esophageal cancer-related gene 2 detected in genomic DNA is a prognostic marker for esophageal cancer.

Microsatellite analysis in serum DNA as a diagnostic tool for distinction of patients with unknown pancreatic masses.

L1 is associated with micrometastatic spread and poor outcome in colorectal cancer.

A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer.

Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements.

Detection, clinical relevance and specific biological properties of disseminating tumour cells.

Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization.

Review: Biological relevance of disseminated tumor cells in cancer patients.

Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.

Cancer micrometastasis and tumour dormancy.

Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer.

Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance.

HER2 as marker for the detection of circulating tumor cells.

Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer.

Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer.

Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion.

Pathology: are circulating tumor cells predictive of overall survival?

Cancer micrometastases.

Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer.

Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/ progenitor cell protein profile.

Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer.

Molecular analysis of the polymorphisms of thymidylate synthase on cell-free circulating DNA in blood of patients with advanced colorectal carcinoma.

Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients.

Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies.

Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.

Discovery of a novel unfolded protein response phenotype of cancer stem/progenitor cells from the bone marrow of breast cancer patients.

Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern.

Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications.

BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood.

Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients.

What's new on circulating tumor cells? A meeting report.

Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.

Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells.

Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer.

Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression.

The GNAS1 T393C single nucleotide polymorphism predicts the natural postoperative course of complete resected esophageal cancer.

Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer.

Cell-free nucleic acids as biomarkers in cancer patients.

The interrelating dynamics of hypoxic tumor microenvironments and cancer cell phenotypes in cancer metastasis.

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.

Controversies in clinical cancer dormancy.

Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells.

Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease.

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients.

Disseminated tumor cells in pancreatic cancer-an independent prognosticator of disease progression and survival.

VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors.

Quantitative high-resolution genomic analysis of single cancer cells.

Circulating tumors cells as biomarkers: progress toward biomarker qualification.

Circulating epithelial cells in patients with benign colon diseases.

Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells.

Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients.

Opposite roles of FOXA1 and NKX2-1 in lung cancer progression.

The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer.

Relevance of PTEN loss in brain metastasis formation in breast cancer patients.

Disseminated tumor cells in bone marrow and the natural course of resected esophageal cancer.

Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors.

Considerations in the development of circulating tumor cell technology for clinical use.

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.

Low-grade and high-grade mammary carcinomas in WAP-T transgenic mice are independent entities distinguished by Met expression.

Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression.

Circulating tumor-derived biomarkers in lung cancer.

Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer.

Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases.

Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.

Definition of molecular determinants of prostate cancer cell bone extravasation.

Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer.

Biologic challenges in the detection of circulating tumor cells.

Circulating tumor cells as therapy-related biomarkers in cancer patients.

Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions.

EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer.

Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing.

Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma.

Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.

Tracking tumor resistance using 'liquid biopsies'.

Dual roles of the transcription factor grainyhead-like 2 (GRHL2) in breast cancer.

Functional activity of RLIM/Rnf12 is regulated by phosphorylation-dependent nucleocytoplasmic shuttling.

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma.

Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients.

CXCR7 expression in esophageal cancer.

Tumor-Induced Osteoclast miRNA Changes as Regulators and Biomarkers of Osteolytic Bone Metastasis.

Real-time liquid biopsy in cancer patients: fact or fiction?

Prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity.

Advances in circulating tumor cells (ACTC): from basic research to clinical practice.

AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

International study on inter-reader variability for circulating tumor cells in breast cancer.

Tumor signatures in the blood.

Prognostic impact of perineural, blood and lymph vessel invasion for esophageal cancer.

Squamous cell carcinoma of the oral cavity and circulating tumour cells.

Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.

Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients.

Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients.

Hematogenous dissemination of glioblastoma multiforme.

Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.

The dynamic range of circulating tumor DNA in metastatic breast cancer.

Mutant p53 promotes epithelial-mesenchymal plasticity and enhances metastasis in mammary carcinomas of WAP-T mice.

PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis.

Real-time liquid biopsy: circulating tumor cells versus circulating tumor DNA.

Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients.

Identification of HERC5 and its potential role in NSCLC progression.

An A/C germline single-nucleotide polymorphism in the TNFAIP3 gene is associated with advanced disease stage and survival in only surgically treated esophageal cancer.

Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein.

Biology, detection, and clinical implications of circulating tumor cells.

Establishment and characterization of a cell line from human circulating colon cancer cells.

Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2.

Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs.

Epithelial-mesenchymal plasticity is a decisive feature for the metastatic outgrowth of disseminated WAP-T mouse mammary carcinoma cells.

The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.

Do circulating tumor cells have a role in deciding on adjuvant chemotherapy after radical cystectomy?

Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.

Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression.

Diverse expression patterns of the EMT suppressor grainyhead-like 2 (GRHL2) in normal and tumour tissues.

Whole Genome Amplification in Genomic Analysis of Single Circulating Tumor Cells.

Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients.

Data Normalization Strategies for MicroRNA Quantification.

Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer.

Circulating DNA as biomarker in breast cancer.

A Versatile Microarray Platform for Capturing Rare Cells.

Heterogeneity of miR-10b expression in circulating tumor cells.

Tumour exosome integrins determine organotropic metastasis.

Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients.

Iroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cells.

Disseminated Tumor Cells Persist in the Bone Marrow of Breast Cancer Patients through Sustained Activation of the Unfolded Protein Response.

Evaluation of the germline single nucleotide polymorphism rs583522 in the TNFAIP3 gene as a prognostic marker in esophageal cancer.

Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells.

Potential Involvement of Jagged1 in Metastatic Progression of Human Breast Carcinomas.

Breast cancer brain metastases: biology and new clinical perspectives.

Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.

Potential of circulating tumor cells as blood-based biomarkers in cancer liquid biopsy.

Functional studies on circulating and disseminated tumor cells in carcinoma patients.

RHAMM splice variants confer radiosensitivity in human breast cancer cell lines.

Liquid biopsy: Potential and challenges.

Genetic traits for hematogeneous tumor cell dissemination in cancer patients.

Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer.

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.

Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm.

Heterogeneous PSMA expression on circulating tumor cells: a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer.

Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®.

Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?

Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.

TP53 mutations on circulating cell-free DNA.

Chronic UVB-irradiation actuates perpetuated dermal matrix remodeling in female mice: Protective role of estrogen.

Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.

Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells.

A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy.

Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer.

Cancer: A shocking protein complex.

Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer.

Liquid biopsies for surveillance and monitoring treatment response of bladder cancer.

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.

Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients.

PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression.

Epithelial-mesenchymal plasticity in circulating tumor cells.

Blood-Based Analysis of Circulating Cell-Free DNA and Tumor Cells for Early Cancer Detection.

Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy.

Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.

Liquid Biopsies, What We Do Not Know (Yet).

Catch and Release: rare cell analysis from a functionalised medical wire.

Cancer stem cells: The root of tumor recurrence and metastases.

Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.

Expression of Epithelial Mesenchymal Transition and Cancer Stem Cell Markers in Circulating Tumor Cells.

Plasma microRNA signature is associated with risk stratification in prostate cancer patients.

Nanoplatforms for Circulating Tumor Cell Detection in Lung Cancer.

Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial.

Tracing the Seeds in the Soil.

Biology and clinical significance of circulating tumor cell subpopulations in lung cancer.

Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells.

Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study.

Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients.

Disseminated breast tumour cells: biological and clinical meaning.

Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection.

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer.

Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy.

In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and Point Mutations in Circulating Tumor Cells.

Clinical applications of the CellSearch platform in cancer patients.

Advances in liquid biopsy approaches for early detection and monitoring of cancer.

Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer.

BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells.

Hemodynamic Forces Tune the Arrest, Adhesion, and Extravasation of Circulating Tumor Cells.

Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of anti-angiogenic therapy.

Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.